SAREPTA THERAPEUTICS INC's ticker is SRPT and the CUSIP is 803607100. A total of 351 filers reported holding SAREPTA THERAPEUTICS INC in Q3 2019. The put-call ratio across all filers is 1.07 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2024 | $1,975,316 | -11.3% | 12,502 | -27.3% | 0.02% | -10.7% |
Q1 2024 | $2,225,935 | +31.1% | 17,194 | -2.4% | 0.03% | +21.7% |
Q4 2023 | $1,698,325 | -15.7% | 17,612 | +6.0% | 0.02% | -25.8% |
Q3 2023 | $2,013,464 | +7.5% | 16,610 | +1.5% | 0.03% | +19.2% |
Q2 2023 | $1,873,547 | -19.0% | 16,360 | -2.5% | 0.03% | -31.6% |
Q1 2023 | $2,311,960 | +4.9% | 16,774 | -1.4% | 0.04% | -7.3% |
Q4 2022 | $2,204,285 | +17.1% | 17,011 | -0.1% | 0.04% | +24.2% |
Q3 2022 | $1,882,000 | +234.9% | 17,027 | +127.0% | 0.03% | +230.0% |
Q2 2022 | $562,000 | -4.1% | 7,500 | -0.1% | 0.01% | +100.0% |
Q1 2022 | $586,000 | -16.6% | 7,504 | -3.9% | 0.01% | +25.0% |
Q4 2021 | $703,000 | -3.0% | 7,808 | -0.4% | 0.00% | 0.0% |
Q3 2021 | $725,000 | +15.8% | 7,841 | -2.6% | 0.00% | +33.3% |
Q2 2021 | $626,000 | +4.3% | 8,047 | -0.0% | 0.00% | 0.0% |
Q1 2021 | $600,000 | -99.5% | 8,049 | -98.8% | 0.00% | -99.5% |
Q4 2020 | $110,368,000 | -9.1% | 647,355 | -25.1% | 0.55% | -26.7% |
Q3 2020 | $121,366,000 | -15.9% | 864,248 | -3.9% | 0.75% | -33.7% |
Q2 2020 | $144,253,000 | +58.9% | 899,671 | -3.1% | 1.13% | +3.7% |
Q1 2020 | $90,805,000 | -25.4% | 928,282 | -1.6% | 1.09% | -13.8% |
Q4 2019 | $121,789,000 | +70.1% | 943,811 | -0.7% | 1.26% | +54.0% |
Q3 2019 | $71,587,000 | -52.5% | 950,441 | -4.2% | 0.82% | -46.0% |
Q2 2019 | $150,735,000 | +27.4% | 992,007 | -0.0% | 1.52% | +20.4% |
Q1 2019 | $118,281,000 | +11.1% | 992,371 | +1.7% | 1.26% | -16.2% |
Q4 2018 | $106,479,000 | -32.7% | 975,705 | -0.4% | 1.51% | -6.6% |
Q3 2018 | $158,214,000 | +21.4% | 979,595 | -0.6% | 1.61% | +14.9% |
Q2 2018 | $130,313,000 | +76.2% | 985,874 | -1.3% | 1.40% | +53.3% |
Q1 2018 | $73,972,000 | +52.3% | 998,404 | +14.4% | 0.92% | +40.5% |
Q4 2017 | $48,564,000 | +100.5% | 872,824 | +63.4% | 0.65% | +91.2% |
Q3 2017 | $24,226,000 | +4874.5% | 534,087 | +3599.4% | 0.34% | +4771.4% |
Q2 2017 | $487,000 | +12.2% | 14,437 | -1.5% | 0.01% | 0.0% |
Q1 2017 | $434,000 | +45.2% | 14,659 | +34.7% | 0.01% | +16.7% |
Q4 2016 | $299,000 | -69.8% | 10,885 | -32.6% | 0.01% | -64.7% |
Q3 2016 | $991,000 | +188.9% | 16,145 | -10.3% | 0.02% | +142.9% |
Q2 2016 | $343,000 | -2.6% | 17,990 | -0.2% | 0.01% | 0.0% |
Q1 2016 | $352,000 | -49.6% | 18,031 | -0.3% | 0.01% | -36.4% |
Q4 2015 | $698,000 | +161.4% | 18,090 | +117.2% | 0.01% | +175.0% |
Q3 2015 | $267,000 | +5.1% | 8,327 | -0.1% | 0.00% | +33.3% |
Q2 2015 | $254,000 | +11.4% | 8,339 | -51.4% | 0.00% | 0.0% |
Q1 2015 | $228,000 | -96.4% | 17,159 | -96.1% | 0.00% | -96.8% |
Q4 2014 | $6,389,000 | -64.0% | 441,533 | -47.5% | 0.10% | -63.2% |
Q3 2014 | $17,745,000 | -29.5% | 840,982 | -0.5% | 0.26% | -22.8% |
Q2 2014 | $25,182,000 | +24.2% | 845,302 | +0.2% | 0.33% | +21.0% |
Q1 2014 | $20,270,000 | +17.8% | 843,534 | -0.1% | 0.28% | +12.2% |
Q4 2013 | $17,205,000 | -57.0% | 844,611 | -0.3% | 0.25% | -60.6% |
Q3 2013 | $40,031,000 | -99.9% | 847,571 | -8.5% | 0.62% | -6.0% |
Q2 2013 | $35,244,199,000 | – | 926,528 | – | 0.66% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Evolutionary Tree Capital Management, LLC | 68,937 | $5,138,000 | 3.04% |
Avoro Capital Advisors LLC | 2,150,000 | $160,240,000 | 2.77% |
Casdin Capital, LLC | 550,000 | $40,992,000 | 1.22% |
TOBAM | 371,107 | $27,659,000 | 1.18% |
Ikarian Capital, LLC | 455,900 | $33,978,000 | 1.14% |
Eventide Asset Management | 697,156 | $51,959,000 | 0.77% |
FOX RUN MANAGEMENT, L.L.C. | 4,902 | $365,000 | 0.66% |
INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 31,500 | $2,348,000 | 0.62% |
Sivik Global Healthcare LLC | 20,000 | $1,491,000 | 0.54% |
Rock Springs Capital Management LP | 328,750 | $24,502,000 | 0.54% |